1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA). This funding opportunity supports exploratory/developmental research on current topics in Alzheimer's disease and its related dementias. It is a 'parent' NOFO under which NIA will issue other related notices describing high-priority research topics.
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Aging (NIA)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NOT-AG-25-023: Notice of Early Expiration of PAR-25-331, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" Notice of Early Expiration of PAR-25-331, "Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)" December 30, 2024 - Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional).
See NOFO PAR-25-331 . This Notice informs applicants that, effective immediately, PAR-25-331 , Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is expired. No further applications will be accepted for PAR-25-331 .
However, applicants can submit an unsolicited grant application to any of the NIH Parent NOFOs . For more information regarding PAR-25-331 , applicants may refer to NIAs web page . Please direct all inquiries to: NIA Scientific Program Contact Weekly TOC for this Announcement NIH...
Turning Discovery Into Health ®
According to the current listing, eligibility includes: Not specified, but R21 grants typically support exploratory and developmental research projects. Confirm the full requirements in the official notice before applying.
Applications for Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) are due November 6, 2027. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional) is funded by National Institute on Aging (NIA). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute on Aging (NIA), National Institutes of Health (NIH). This program supports small molecule drug discovery and development for disorders of the nervous system, including Alzheimer's disease and related dementias.
NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute on Aging (NIA) - NIH. NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute o…
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
Innovation Grant is a grant from the Delta Dental of Arizona Foundation that funds nonprofit organizations pursuing unique, high-impact projects that improve health and wellness in Arizona communities. This two-year award supports original initiatives with measurable real-world impact, including programs serving underserved and uninsured populations through oral health education, disease prevention, and nutritional access. Projects must demonstrate the potential to make a meaningful difference in the community and stand apart from conventional approaches. Eligible applicants are Arizona-based nonprofit organizations. Awards total $100,000 per recipient over two years. The 2026 application cycle closed October 16, 2025, with recipients notified in late 2025 and funding made available shortly after.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article